KPV (Alpha-MSH Fragment) vs Substance P Antagonists
Anti-inflammatory tripeptide from alpha-melanocyte-stimulating hormone targeting NF-κB and gut inflammation
NK1 receptor blockers that reduce pain signals and nausea at the source
Quick comparison
Dose range
KPV (Alpha-MSH Fragment)
300–500 mcg
Substance P Antagonists
150–150 mg
Frequency
KPV (Alpha-MSH Fragment)
Once daily
Substance P Antagonists
Once daily
Administration
KPV (Alpha-MSH Fragment)
Oral
Substance P Antagonists
Oral capsule
Cycle length
KPV (Alpha-MSH Fragment)
Ongoing/indefinite
Substance P Antagonists
Ongoing/indefinite
Onset speed
KPV (Alpha-MSH Fragment)
Moderate (1-2 weeks)
Substance P Antagonists
Moderate (1-2 weeks)
Evidence level
KPV (Alpha-MSH Fragment)
Strong human trials (Phase 3 or FDA approved)
Substance P Antagonists
Moderate human trials (Phase 1-2)
Benefit ratings
Anti-Inflammatory
Gut Health
Healing & Recovery
Anti-Nausea & Antiemetic
Pain Modulation
Neuroprotection
Compound specifications
KPV (Alpha-MSH Fragment)
Molecular formula
C16H30N4O4
Molecular weight
342.43 Da
Half-life
Short peptide half-life; improved by nanoparticle and hydrogel formulations
Bioavailability
Oral uptake via PepT1 transporter; enhanced by nanoparticle formulations
CAS number
67727-97-3
Substance P Antagonists
Molecular formula
C23H21F7N4O3
Molecular weight
534.4 g/mol
Half-life
9-13 hours (elimination half-life)
Bioavailability
Approximately 60-65% oral bioavailability; food may increase absorption
CAS number
170729-80-3
Dosing compared
KPV (Alpha-MSH Fragment)
Subcutaneous
200 mcg
Once daily · 4-6 weeks
Lower end of the subcutaneous practice range for systemic anti-inflammatory use; KPV is the C-terminal tripeptide of alpha-MSH and acts on NF-kB signaling [3][6].
300-500 mcg
Once daily · 4-6 weeks
Most commonly used subcutaneous practice dose for systemic/extra-intestinal inflammation; some practitioners escalate toward 500 mcg during acute flares [6].
Oral
1000-1500 mcg
Once daily · 4-6 weeks
Oral route is used for gut-directed effects (e.g., IBD/ulcerative colitis models), taking advantage of PepT1 uptake; preclinical colitis studies support this application, doses are research practice [2][6].
Topical
0.01-0.1% cream or serum
Twice daily · 7-14 days (acute) up to 4-8 weeks (chronic)
Applied as a 0.01-0.1% topical formulation to affected skin for localized inflammation (eczema, rosacea, post-procedure redness); penetration enhancers are often added. Research/practice use [6].
Substance P Antagonists
Intravenous
150 mg (fosaprepitant)
Single dose, 30 min before chemotherapy on day 1 · One dose per chemotherapy cycle
FDA-approved single-dose IV prodrug regimen, with a 5-HT3 antagonist and corticosteroid [5].
Oral
125 mg on day 1, then 80 mg on days 2-3 (aprepitant)
Once daily · 3-day course per chemotherapy cycle
FDA-approved oral regimen: 125 mg 1 hour before chemotherapy, then 80 mg each morning on days 2 and 3 [5].
Best suited for
KPV (Alpha-MSH Fragment)
Inflammatory bowel disease research
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on inflammatory bowel disease research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Gut anti-inflammatory therapy development
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on gut anti-inflammatory therapy development. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Skin inflammation and wound healing
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on skin inflammation and wound healing. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Cytokine-mediated inflammation studies
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on cytokine-mediated inflammation studies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Substance P Antagonists
Managing severe nausea from cancer treatments
Substance P Antagonists is particularly well-suited for individuals focused on managing severe nausea from cancer treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Chronic pain reduction
Substance P Antagonists is particularly well-suited for individuals focused on chronic pain reduction. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Improving quality of life during intensive medical therapy
Substance P Antagonists is particularly well-suited for individuals focused on improving quality of life during intensive medical therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Side effects
KPV (Alpha-MSH Fragment)
Common
- Injection Site Reaction
- Mild GI Effects
- Transient Skin Effects
- Mild Immune Modulation
- Peptide Stability Concerns
Uncommon
- Theoretical Immunosuppression
Serious
- Immune Tolerance Development
Substance P Antagonists
Common
- Headache
- Fatigue or weakness
- Constipation
Uncommon
- Loss of appetite
- Dizziness
Serious
- Stevens-Johnson Syndrome (SJS)
Safety & evidence
KPV (Alpha-MSH Fragment)
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
Research compound
Safety overview
KPV is a tripeptide fragment of alpha-MSH with excellent tolerability in preclinical models and limited human safety data. The compound shows immunomodulatory properties targeting anti-inflammatory pathways (IL-1 and TNF-alpha suppression) rather than broad immune activation, potentially making it safer for individuals concerned about excessive immune stimulation. Skin darkening and appetite stimulation are documented alpha-MSH effects but less pronounced with the KPV fragment. Safety remains largely determined by route and dose, with cutaneous application showing minimal systemic absorption.
Contraindications
- Not approved for human clinical use
- Unknown interactions with immunosuppressive medications
- Insufficient safety data for pregnancy and lactation
- Potential melanocortin receptor effects in susceptible individuals
Substance P Antagonists
Evidence level
Moderate human trials (Phase 1-2)
FDA status
FDA approved for this use
Safety overview
Aprepitant (the primary NK1 antagonist) has been FDA-approved since 2003 with extensive safety data in over 50,000 cancer patients receiving highly emetogenic chemotherapy. Most common adverse events are mild to moderate—headache (15-20%), fatigue, and constipation—which are often difficult to attribute solely to aprepitant versus underlying malignancy or chemotherapy effects. Serious but rare adverse events include Stevens-Johnson syndrome (extremely uncommon) and QT prolongation (in susceptible individuals), requiring baseline ECG evaluation in high-risk patients.
Contraindications
- Severe hypersensitivity to aprepitant or any component
- Concurrent use with certain other medications that affect the liver
- Severe cardiac conditions
Which is right for you?
Choose KPV (Alpha-MSH Fragment) if...
- Inflammatory bowel disease research
- Gut anti-inflammatory therapy development
- Skin inflammation and wound healing
- Cytokine-mediated inflammation studies
Choose Substance P Antagonists if...
- Managing severe nausea from cancer treatments
- Chronic pain reduction
- Improving quality of life during intensive medical therapy